US3474777A - Method of administering therapeutic agents - Google Patents

Method of administering therapeutic agents Download PDF

Info

Publication number
US3474777A
US3474777A US526361A US3474777DA US3474777A US 3474777 A US3474777 A US 3474777A US 526361 A US526361 A US 526361A US 3474777D A US3474777D A US 3474777DA US 3474777 A US3474777 A US 3474777A
Authority
US
United States
Prior art keywords
therapeutic agent
organism
substance
magnetically responsive
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US526361A
Inventor
Frank H J Figge
Guiles Flower Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TE Connectivity Corp
Original Assignee
AMP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMP Inc filed Critical AMP Inc
Application granted granted Critical
Publication of US3474777A publication Critical patent/US3474777A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting

Definitions

  • This invention relates to methods of localizing a therapeutic agent at a preferred treatment site within an organism and to therapeutic agents for use in practising such methods.
  • therapeutic substances while exerting beneficial eifects on certain portions of a diseased organism, may detrimentally aflfect other, healthy, portions of the organism. If therapeutic agents of this type are localized within the organism at those sites specifically desired to be treated with the therapeutic agent, without being dispersed generally throughout the organism, the beneficial effect of the therapeutic agent is maximized while possibly harmful elfects are minimized or eliminated.
  • the present invention relates to a method of localizing a threapeutic agent at a preferred treatment site within an organism by introducing said therapeutic agent into the organism in association with a magnetically responsive substance.
  • the magnetically responsive substance and the therapeutic agent are then directed, localized, or concentrated within the organism under the influence of magnetic fields applied to the organism or to those portions of the organism to be treated.
  • the therapeutic agent acts locally without being generally dispersed throughout the organism.
  • the therapeutic agent and associated magnetic substance can be recovered from the organism, if their continued presence is unnecessary ordetrimental, by methods discussed hereinafter.
  • the therapeutic agent and magnetic substance are dissociated within the organism, and only the magnetic substance is recovered.
  • therapeutic agent herein is meant, broadly, a substance or substances having an ultimate beneficial effeet on an organism.
  • the term as used in the present specification and claims may include materials, such. as radioactive substances, which are harmful to or destructive of living tissue. The use of such radioactive materials to destroy abnormal tissue, however, would constitute an ultimate beneficial effect to the organism and such substances are considered herein as therapeutic agents.
  • a magnetically responsive substance as used in the specification and claims of this application is meant a material which responds to and/or can be directed spatially by a magnetic field or fields.
  • the responsive substances need not be paramagnetic, although such substances are most commonly thought of as being magnetic in the conventional sense, but may also be diamagnetic.
  • the materials may be elements or compounds, or components of compounds, and need have no particular physical form providing only that they can be influenced in their direction of movement by a magnetic field.
  • the association between the therapeutic agent and the magnetically responsive substance may be of diverse types. Most commonly, the agent and magnetic substance are associated together in the form of discrete particles, which particles may have the form of microcapsules. Thus, a magnetically responsive substance as understood herein may be coated with or dispersed within a therapeutic agent or, conversely, a magnetically responsive substance may be used to coat or partially coat a therapeutic agent, or as a matrix for the agent. When the particles are employed in the form of microcapsules, the magnetically responsive substance may be within the capsule shell, or the magnetic substance may form part of a shell encapsulating a therapeutic agent.
  • the association between the therapeutic agent and the magnetically responsive substance may be on an atomic scale, for instance where the therapeutic agent comprises a radioactive isotope prepared by irradiation or bombardment of particles of a magnetically responsive substance.
  • the radioactive therapeutic agent comprising a transmuted form of the magnetically responsive substance, is dispersed atomically throughout the magnetically responsive substance.
  • the therapeutic agent and magnetically responsive substance may be one and the same, as in the case of magnetic radioactive isotopes.
  • U.S. Patent 3,042,416 discloses the coating of magnetic particles of very small diameter.
  • U.S. Patent 3,190,837 discloses methods of encapsulating various materials, specifically including solid magnetic materials.
  • particles comprising a therapeutic agent and an associated magnetically responsive substance should be sufficiently small to pass freely through the capillaries.
  • average capillary diameter is about 78 microns, a size accommodating the red blood cells, which are about seven microns in size.
  • therapeutiomagnetic particles of the type contemplated by the invention would suitably have an average size of up to about 5 microns.
  • the particles can be moved within the capillaries by movement or rotation of the magnetic field to alter the position of the magnetically responsive particles during treatment.
  • the magnetically responsive substances, and/or other inert substances having no therapeutic effect but used as coatings, to form capsule shell walls, etc. should be materials compatible with the organism, e.g. substances compatible with animal body fluids, or not forming clots when present in the blood stream of animals.
  • such microscopic particles are introduced into the organism by injection.
  • the introduction of a therapeutic agent into the capillary bed of animal tissue is of particular importance, and may be effected either by intravenous injection or injection into an artery.
  • the therapeutic agent may be localized by control of the magnetically responsive substance in association therewith under the influence of applied magnetic fields.
  • the magnetic fields may be established by permanent magnets, or by electromagnets, and may be altered in size, shape, and strength to adapt them to particular situations.
  • the detection of localization of the magnetically responsive substance and associated therapeutic agent may be done by chemical analysis. Fluoroscopic or roentgenographic examination of the organism also offers a ready means of detection, since the magnetically responsive substances are commonly relatively opaque to X-rays.
  • Dissociation or release of a therapeutic agent from a magnetic substance is preferably initiated or promoted, if appropriate, after the therapeutic agent has been localized in an organism by magnetic direction of the magnetically responsive substance associated therewith.
  • This dissociation may merely involve the lapse of time, as, for example, in the loss of the therapeutic properties of a radioactive isotope by partial or complete radioactive decay.
  • Dissociation may also be effected by external agencies, such as the use of high frequency sound waves to rupture the coatings of microcapsules containing a therapuetic agent within the capsules. Most commonly, release of the therapeutic agent is effected by some agency internal to the organism.
  • a therapeutic coating on a magnetically responsive substance may simply be released with time by solution of the therapeutic agent in natural fluids of the organisms. Further, the release of a therapeutic agent from association with a magnetic substance may be initiated or speeded in response to still another substance injected or ingested into the organism after localization of the therapeutic agent in situ has been effected.
  • the magnetically responsive substance may be recovered from the organism if its continued presence is undesirable.
  • magnetic fields localizing magnetic particles in particular tissues may be removed, permitting the particles to circulate in the blood stream.
  • the particles can be localized to simplify their removal. Permitting the blood to pass through a simple T-tube connection in which one arm of the T is maintained in a magnetic field will cause magnetically responsive substances in the blood to be attracted by the magnetic field and to be retained in the arm of the tube. The substances are thus isolated from the blood of the animal.
  • the methods of the present invention can be utilized for the administration of local anesthesia, for example, both within tissues generally or in the spinal fluid of a vertebrate.
  • Endocrine glands can be stimulated or inhibited by the administration of drugs or other endocrine substances whose effects are localized in the glands.
  • Cortisone or cortisone-like substances for example, can be administered directly to rheumatic joints while minimizing side effects such as ulcers, edema, and endocrine upset associated with general dispersal of cortisone through an animal organism.
  • Abnormal or cancerous tissue can also be treated.
  • Such abnormal tissue can presently be destroyed, or the cells thereof rendered incapable of further reproduction, by a variety of compounds known to the art, including materials such as 6-mercaptopurine, buslfan, chlorambucil, methotrexate, nitrogen mustards, azetepa, fluorouracil, or 5-fluoro-deoxyuridine.
  • materials such as 6-mercaptopurine, buslfan, chlorambucil, methotrexate, nitrogen mustards, azetepa, fluorouracil, or 5-fluoro-deoxyuridine.
  • the maximum dose of such a therapuetic agent which can be administered is determined solely by the maximum detrimental effect which can be tolerated by portions of the organism other than that being treated. Using the methods of the present invention, the severe side effects of these drugs on healthy tissue can be minimized without loss of effect on abnormal tissue being treated.
  • said therapeutic agent comprises a radioactive isotope.
  • said therapeutic agent comprises a substance antagonistic to abnormal cell growth.
  • Microcapsules adaptable to injection and having a maximum particle size of about five microns, said microcapsules comprising a therapeutic agent in association with a magneticaly responsive substance.
  • Finely-divided particles of a magnetically responsive substance having a coating of a therapeutic agent thereon said particles being adaptable to injection and having a maximum particle size of about five microns.
  • Particles as in claim 11 wherein said therapeutic agent is a substance antagonistic to abnormal cell growth.

Description

United States Patent 3,474,777 METHOD OF ADMINISTERING THERAPEUTIC AGENTS Frank H. J. Figge, Towson, Md., and Guiles Flower, In,
Carlisle, Pa., assignors to AMP Incorporated, Harrisburg, Pa., a corporation of New Jersey N0 Drawing. Filed Feb. 10, 1966, Ser. No. 526,361 Int. Cl. A6111 5/00; A6111 5/10 U.S. Cl. 128-22 13 Claims ABSTRACT OF THE DISCLOSURE Method of localizing a therapeutic agent at a preferred treatment site within an organism by injecting said agent into the organism in association with a magnetically responsive substance and concentrating the agent and substance at the preferred treatment site by the application of magnetic fields to the organism. Microcapsules and/or particles adaptable to injection and having a maximum size of five microns, said microcapsules and/ or particles comprising a therapeutic agent in association with a magnetically responsive substance.
This invention relates to methods of localizing a therapeutic agent at a preferred treatment site within an organism and to therapeutic agents for use in practising such methods.
Numerous therapeutic substances, while exerting beneficial eifects on certain portions of a diseased organism, may detrimentally aflfect other, healthy, portions of the organism. If therapeutic agents of this type are localized within the organism at those sites specifically desired to be treated with the therapeutic agent, without being dispersed generally throughout the organism, the beneficial effect of the therapeutic agent is maximized while possibly harmful elfects are minimized or eliminated.
The present invention relates to a method of localizing a threapeutic agent at a preferred treatment site within an organism by introducing said therapeutic agent into the organism in association with a magnetically responsive substance. The magnetically responsive substance and the therapeutic agent are then directed, localized, or concentrated within the organism under the influence of magnetic fields applied to the organism or to those portions of the organism to be treated. When the therapeutic agent is thus localized within the organism in association with a magnetically responsive substance, the position or location of which substance in turn is controlled by the applied magnetic field, the therapeutic agent acts locally without being generally dispersed throughout the organism. Subsequently, the therapeutic agent and associated magnetic substance can be recovered from the organism, if their continued presence is unnecessary ordetrimental, by methods discussed hereinafter. In other embodiments, the therapeutic agent and magnetic substance are dissociated within the organism, and only the magnetic substance is recovered.
By therapeutic agent herein is meant, broadly, a substance or substances having an ultimate beneficial effeet on an organism. Thus, the term as used in the present specification and claims may include materials, such. as radioactive substances, which are harmful to or destructive of living tissue. The use of such radioactive materials to destroy abnormal tissue, however, would constitute an ultimate beneficial effect to the organism and such substances are considered herein as therapeutic agents.
By a magnetically responsive substance as used in the specification and claims of this application is meant a material which responds to and/or can be directed spatially by a magnetic field or fields. The responsive substances need not be paramagnetic, although such substances are most commonly thought of as being magnetic in the conventional sense, but may also be diamagnetic. The materials may be elements or compounds, or components of compounds, and need have no particular physical form providing only that they can be influenced in their direction of movement by a magnetic field.
The association between the therapeutic agent and the magnetically responsive substance may be of diverse types. Most commonly, the agent and magnetic substance are associated together in the form of discrete particles, which particles may have the form of microcapsules. Thus, a magnetically responsive substance as understood herein may be coated with or dispersed within a therapeutic agent or, conversely, a magnetically responsive substance may be used to coat or partially coat a therapeutic agent, or as a matrix for the agent. When the particles are employed in the form of microcapsules, the magnetically responsive substance may be within the capsule shell, or the magnetic substance may form part of a shell encapsulating a therapeutic agent. In still a further embodiment, the association between the therapeutic agent and the magnetically responsive substance may be on an atomic scale, for instance where the therapeutic agent comprises a radioactive isotope prepared by irradiation or bombardment of particles of a magnetically responsive substance. In such a case, the radioactive therapeutic agent, comprising a transmuted form of the magnetically responsive substance, is dispersed atomically throughout the magnetically responsive substance. Finally, the therapeutic agent and magnetically responsive substance may be one and the same, as in the case of magnetic radioactive isotopes.
U.S. Patent 2,971,916, for example, discloses the manufacture of microscopic capsules comprising a magnetizable material. U.S. Patent 3,042,416 discloses the coating of magnetic particles of very small diameter. U.S. Patent 3,190,837 discloses methods of encapsulating various materials, specifically including solid magnetic materials.
For localization within the capillary bed of animal tissue, particles comprising a therapeutic agent and an associated magnetically responsive substance should be sufficiently small to pass freely through the capillaries. In the mouse and many other vertebrates, for example, average capillary diameter is about 78 microns, a size accommodating the red blood cells, which are about seven microns in size. Hence, for use in mice, for example, therapeutiomagnetic particles of the type contemplated by the invention would suitably have an average size of up to about 5 microns. Since about twothirds of the capillary vessels within a capillary bed are not normally engorged with blood except when circulation is stimulated by exercise, there is little chance of complete blockage of all the blood vessels of a capillary bed on introduction thereinto of particles of the type described. Also, during treatment, the particles can be moved within the capillaries by movement or rotation of the magnetic field to alter the position of the magnetically responsive particles during treatment. As will be evident to those skilled in the art, the magnetically responsive substances, and/or other inert substances having no therapeutic effect but used as coatings, to form capsule shell walls, etc. should be materials compatible with the organism, e.g. substances compatible with animal body fluids, or not forming clots when present in the blood stream of animals.
In the present invention, such microscopic particles are introduced into the organism by injection. The introduction of a therapeutic agent into the capillary bed of animal tissue is of particular importance, and may be effected either by intravenous injection or injection into an artery.
One injected into the organism, the therapeutic agent may be localized by control of the magnetically responsive substance in association therewith under the influence of applied magnetic fields. As will be evident to those skilled in the art, the magnetic fields may be established by permanent magnets, or by electromagnets, and may be altered in size, shape, and strength to adapt them to particular situations. The detection of localization of the magnetically responsive substance and associated therapeutic agent may be done by chemical analysis. Fluoroscopic or roentgenographic examination of the organism also offers a ready means of detection, since the magnetically responsive substances are commonly relatively opaque to X-rays.
Dissociation or release of a therapeutic agent from a magnetic substance is preferably initiated or promoted, if appropriate, after the therapeutic agent has been localized in an organism by magnetic direction of the magnetically responsive substance associated therewith. This dissociation may merely involve the lapse of time, as, for example, in the loss of the therapeutic properties of a radioactive isotope by partial or complete radioactive decay. Dissociation may also be effected by external agencies, such as the use of high frequency sound waves to rupture the coatings of microcapsules containing a therapuetic agent within the capsules. Most commonly, release of the therapeutic agent is effected by some agency internal to the organism. For example, a therapeutic coating on a magnetically responsive substance may simply be released with time by solution of the therapeutic agent in natural fluids of the organisms. Further, the release of a therapeutic agent from association with a magnetic substance may be initiated or speeded in response to still another substance injected or ingested into the organism after localization of the therapeutic agent in situ has been effected.
After therapeutic treatment has been completed, or the therapeutic agent and magnetically responsive substance have been dissociated, the magnetically responsive substance may be recovered from the organism if its continued presence is undesirable. For example, in an animal, magnetic fields localizing magnetic particles in particular tissues may be removed, permitting the particles to circulate in the blood stream. By passing the blood through a magnetic trap external to the organism, the particles can be localized to simplify their removal. Permitting the blood to pass through a simple T-tube connection in which one arm of the T is maintained in a magnetic field will cause magnetically responsive substances in the blood to be attracted by the magnetic field and to be retained in the arm of the tube. The substances are thus isolated from the blood of the animal.
The methods of the present invention can be utilized for the administration of local anesthesia, for example, both within tissues generally or in the spinal fluid of a vertebrate. Endocrine glands can be stimulated or inhibited by the administration of drugs or other endocrine substances whose effects are localized in the glands. Cortisone or cortisone-like substances, for example, can be administered directly to rheumatic joints while minimizing side effects such as ulcers, edema, and endocrine upset associated with general dispersal of cortisone through an animal organism. Abnormal or cancerous tissue can also be treated.
Such abnormal tissue can presently be destroyed, or the cells thereof rendered incapable of further reproduction, by a variety of compounds known to the art, including materials such as 6-mercaptopurine, buslfan, chlorambucil, methotrexate, nitrogen mustards, azetepa, fluorouracil, or 5-fluoro-deoxyuridine. Compounds of this type,
although highly effective in destroying unwanted tissue, also attack tissue in other portions 'of the organism since they must, in the present state of the art, be introduced into the blood stream and dispersed generally throughout the organism. -In many cases, the maximum dose of such a therapuetic agent which can be administered is determined solely by the maximum detrimental effect which can be tolerated by portions of the organism other than that being treated. Using the methods of the present invention, the severe side effects of these drugs on healthy tissue can be minimized without loss of effect on abnormal tissue being treated.
What is claimed is:
1. The method of localizing a therapeutic agent at a preferred treatment site within an organism which comprises injecting said agent into said organism in association with a magnetically responsive substance and concentrating said agent and substance at said preferred treatment site by the application of magnetic fields to said organism.
2. The method as in claim 1 wherein said therapeutic agent and associated magnetically responsive substance are associated in a plurality of microscopic particles.
3. The method as in claim 2 wherein said microscopic particles comprise microcapsules.
4. The method as in claim 1 wherein said magnetically responsive substance is said therapeutic agent.
5. The method as in claim 1 wherein said therapeutic agent and associated magnetically responsive substance dissociate with time.
6. The method as in claim 1 wherein said therapeutic agent and associated magnetically responsive substance dissociate in response to an agency external to said organism.
7. The method as in claim 1 wheren said therapeutic agent and associated magnetically responsive substance dissociate in response to an agency within said organism.
8. The method as in claim 1 wherein said therapeutic agent comprises a radioactive isotope.
9. The method as in claim 1 wherein said therapeutic agent comprises a substance antagonistic to abnormal cell growth.
10. Microcapsules adaptable to injection and having a maximum particle size of about five microns, said microcapsules comprising a therapeutic agent in association with a magneticaly responsive substance.
11. Finely-divided particles of a magnetically responsive substance having a coating of a therapeutic agent thereon, said particles being adaptable to injection and having a maximum particle size of about five microns.
12. Microcapsules as in claim 10 wherein said therapeutic agent comprises a substance antagonistic to abnormal cell growth.
13. Particles as in claim 11 wherein said therapeutic agent is a substance antagonistic to abnormal cell growth.
References Cited UNITED STATES PATENTS 2,671,451 3/1954 Bolger 12826O 3,057,344 10/1962 Abella et a1. 128-2 3,159,545 12/1964 Kidwell et al. 16751 X OTHER REFERENCES Injection Gun: Cancer treatment tester, Washington Post, Feb. 1, 1968.
ADELE M. EAGER, Primary Examiner US. Cl. X.R.
US526361A 1966-02-10 1966-02-10 Method of administering therapeutic agents Expired - Lifetime US3474777A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52636166A 1966-02-10 1966-02-10

Publications (1)

Publication Number Publication Date
US3474777A true US3474777A (en) 1969-10-28

Family

ID=24097021

Family Applications (1)

Application Number Title Priority Date Filing Date
US526361A Expired - Lifetime US3474777A (en) 1966-02-10 1966-02-10 Method of administering therapeutic agents

Country Status (1)

Country Link
US (1) US3474777A (en)

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373290A1 (en) * 1976-12-11 1978-07-07 Kernforschungsanlage Juelich METHOD FOR THE PREPARATION OF A MASS OF CHARGED CELLS IN SUSPENSION IN A PHYSIOLOGICAL SOLUTION
EP0000667A1 (en) * 1977-08-01 1979-02-07 Northwestern University Intravascularly-administrable, magnetically-localizable biodegradable carrier and process for its preparation
DE2828941A1 (en) * 1978-06-30 1980-01-10 Robert Thomas Gordon CANCER TREATMENT AGENTS
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4303636A (en) * 1974-08-20 1981-12-01 Gordon Robert T Cancer treatment
EP0042249A2 (en) 1980-06-13 1981-12-23 Northwestern University Magnetically-localizable, biodegradable lipid microspheres
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
WO1982002339A1 (en) * 1981-01-09 1982-07-22 Robert W Rand Induction heating method and apparatus for use in causing necrosis of neoplasm
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4359453A (en) * 1978-04-07 1982-11-16 Gordon Robert T Atherosclerosis treatment method
US4590922A (en) * 1983-08-19 1986-05-27 Gordon Robert T Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases
US4622952A (en) * 1983-01-13 1986-11-18 Gordon Robert T Cancer treatment method
US4657543A (en) * 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
WO1987003798A1 (en) * 1985-12-19 1987-07-02 Mirell Stuart G Electromagnetic therapy control system
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4764359A (en) * 1984-05-25 1988-08-16 Lemelson Jerome H Drug compositions and their use in treating human or other mammalian patients
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4779806A (en) * 1984-07-23 1988-10-25 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate
US4889707A (en) * 1988-01-29 1989-12-26 The Curators Of The University Of Missouri Composition and method for radiation synovectomy of arthritic joints
US4983159A (en) * 1985-03-25 1991-01-08 Rand Robert W Inductive heating process for use in causing necrosis of neoplasms at selective frequencies
US5079006A (en) * 1987-07-15 1992-01-07 Aprex Corporation Pharmaceutical compositions containing a magnetically detectable material
US5125888A (en) * 1990-01-10 1992-06-30 University Of Virginia Alumni Patents Foundation Magnetic stereotactic system for treatment delivery
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
US5171215A (en) * 1991-08-22 1992-12-15 Flanagan Dennis F Endermic method and apparatus
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5458597A (en) * 1993-11-08 1995-10-17 Zomed International Device for treating cancer and non-malignant tumors and methods
US5472441A (en) * 1993-11-08 1995-12-05 Zomed International Device for treating cancer and non-malignant tumors and methods
US5486161A (en) * 1993-02-02 1996-01-23 Zomed International Medical probe device and method
US5529568A (en) * 1994-03-18 1996-06-25 Surgery Futures Research, Inc. Magnetic operating table
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5667806A (en) * 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US5766633A (en) * 1993-04-22 1998-06-16 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5913855A (en) * 1995-08-15 1999-06-22 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US5925042A (en) * 1995-08-15 1999-07-20 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US5928229A (en) * 1993-11-08 1999-07-27 Rita Medical Systems, Inc. Tumor ablation apparatus
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5951547A (en) * 1995-08-15 1999-09-14 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5980517A (en) * 1995-08-15 1999-11-09 Rita Medical Systems, Inc. Cell necrosis apparatus
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6059780A (en) * 1995-08-15 2000-05-09 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method with cooling element
US6071280A (en) * 1993-11-08 2000-06-06 Rita Medical Systems, Inc. Multiple electrode ablation apparatus
US6071510A (en) * 1995-03-31 2000-06-06 Emisphere Technologies, Inc. Modified amino acids and compositions comprising the same for delivering active agents
US6080150A (en) * 1995-08-15 2000-06-27 Rita Medical Systems, Inc. Cell necrosis apparatus
US6084112A (en) * 1995-09-11 2000-07-04 Emisphere Technologies, Inc. Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones
US6090105A (en) * 1995-08-15 2000-07-18 Rita Medical Systems, Inc. Multiple electrode ablation apparatus and method
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US6132425A (en) * 1995-08-15 2000-10-17 Gough; Edward J. Cell necrosis apparatus
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6242495B1 (en) 1997-02-07 2001-06-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6375983B1 (en) 1996-06-14 2002-04-23 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US20020136693A1 (en) * 1984-11-23 2002-09-26 Heinz Gries Magnetic particles for diagnostic purposes
US20050033279A1 (en) * 1993-11-08 2005-02-10 Rita Medical Systems, Inc. RF treatment apparatus
US6958062B1 (en) 1993-11-08 2005-10-25 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US20060057211A1 (en) * 2004-02-20 2006-03-16 Michael Chorny Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US7417022B2 (en) 1996-03-29 2008-08-26 Mhr Institutional Partners Iia Lp Compounds and compositions for delivering active agents
US20090082611A1 (en) * 2004-02-20 2009-03-26 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7553872B2 (en) 1997-02-07 2009-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20100241058A1 (en) * 2009-03-19 2010-09-23 Ahmed Syed Yosuf Oct guided tissue ablation
US20100260780A1 (en) * 2004-02-20 2010-10-14 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20130225904A1 (en) * 2012-02-29 2013-08-29 University Of Virginia System and method for magnetic control of an anesthetic
US8734439B2 (en) 1995-08-15 2014-05-27 Angiodynamics, Inc Ablation apparatus and method
US9339664B2 (en) 2009-11-02 2016-05-17 Pulse Therapetics, Inc. Control of magnetic rotors to treat therapeutic targets
US9883878B2 (en) 2012-05-15 2018-02-06 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
US20200069928A1 (en) * 2017-05-29 2020-03-05 Bionaut Labs Ltd. Triggering of payload release from miniaturized devices
US11918315B2 (en) 2019-05-02 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671451A (en) * 1952-06-16 1954-03-09 Stephen J Bolger Remedial pill
US3057344A (en) * 1957-05-21 1962-10-09 Abella Carlos Alberto Capsule for the study of the digestive tract and method of using the same
US3159545A (en) * 1960-10-04 1964-12-01 Abbott Lab Radioactive capsules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671451A (en) * 1952-06-16 1954-03-09 Stephen J Bolger Remedial pill
US3057344A (en) * 1957-05-21 1962-10-09 Abella Carlos Alberto Capsule for the study of the digestive tract and method of using the same
US3159545A (en) * 1960-10-04 1964-12-01 Abbott Lab Radioactive capsules

Cited By (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303636A (en) * 1974-08-20 1981-12-01 Gordon Robert T Cancer treatment
FR2373290A1 (en) * 1976-12-11 1978-07-07 Kernforschungsanlage Juelich METHOD FOR THE PREPARATION OF A MASS OF CHARGED CELLS IN SUSPENSION IN A PHYSIOLOGICAL SOLUTION
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
EP0000667A1 (en) * 1977-08-01 1979-02-07 Northwestern University Intravascularly-administrable, magnetically-localizable biodegradable carrier and process for its preparation
US4359453A (en) * 1978-04-07 1982-11-16 Gordon Robert T Atherosclerosis treatment method
DE2828941A1 (en) * 1978-06-30 1980-01-10 Robert Thomas Gordon CANCER TREATMENT AGENTS
FR2429591A1 (en) * 1978-06-30 1980-01-25 Gordon Robert CANCER TREATMENT METHOD AND COMPOSITION
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
EP0042249A2 (en) 1980-06-13 1981-12-23 Northwestern University Magnetically-localizable, biodegradable lipid microspheres
WO1982002339A1 (en) * 1981-01-09 1982-07-22 Robert W Rand Induction heating method and apparatus for use in causing necrosis of neoplasm
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4622952A (en) * 1983-01-13 1986-11-18 Gordon Robert T Cancer treatment method
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4590922A (en) * 1983-08-19 1986-05-27 Gordon Robert T Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases
US4764359A (en) * 1984-05-25 1988-08-16 Lemelson Jerome H Drug compositions and their use in treating human or other mammalian patients
US4657543A (en) * 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4779806A (en) * 1984-07-23 1988-10-25 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US20020136693A1 (en) * 1984-11-23 2002-09-26 Heinz Gries Magnetic particles for diagnostic purposes
US4983159A (en) * 1985-03-25 1991-01-08 Rand Robert W Inductive heating process for use in causing necrosis of neoplasms at selective frequencies
WO1987003798A1 (en) * 1985-12-19 1987-07-02 Mirell Stuart G Electromagnetic therapy control system
US4690130A (en) * 1985-12-19 1987-09-01 Mirell Stuart G Electromagnetic therapy control system
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate
US5853763A (en) * 1986-10-24 1998-12-29 Southern Research Institute Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their release
US5942252A (en) * 1986-10-24 1999-08-24 Southern Research Institute Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their release
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5820883A (en) * 1986-10-24 1998-10-13 Southern Research Institute Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their release
US5814344A (en) * 1986-10-24 1998-09-29 Southern Research Institute Method for delivering bioactive agents into and through the mucosally associated lymphoid tissues and controlling their release
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5079006A (en) * 1987-07-15 1992-01-07 Aprex Corporation Pharmaceutical compositions containing a magnetically detectable material
US4889707A (en) * 1988-01-29 1989-12-26 The Curators Of The University Of Missouri Composition and method for radiation synovectomy of arthritic joints
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
US6216030B1 (en) 1990-01-10 2001-04-10 The University Of Virginia Alumni Patents Foundation Magnetic stereotactic system for treatment delivery
US5125888A (en) * 1990-01-10 1992-06-30 University Of Virginia Alumni Patents Foundation Magnetic stereotactic system for treatment delivery
US5779694A (en) * 1990-01-10 1998-07-14 The University Of Virginia Alumni Patents Foundation Magnetic stereotactic system for treatment delivery
US5171215A (en) * 1991-08-22 1992-12-15 Flanagan Dennis F Endermic method and apparatus
US6413550B1 (en) 1992-06-15 2002-07-02 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US6245359B1 (en) 1992-06-15 2001-06-12 Emisphere Technologies, Inc. Active agent transport systems
US5840340A (en) * 1992-06-15 1998-11-24 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6071538A (en) * 1992-06-15 2000-06-06 Emisphere Technologies, Inc. Oral delivery composition comprising supramolecular complex
US6348207B1 (en) 1992-06-15 2002-02-19 Emisiphere Technologies, Inc. Orally deliverable supramolecular complex
US5601846A (en) * 1992-06-15 1997-02-11 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5540939A (en) * 1992-12-21 1996-07-30 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5972387A (en) * 1992-12-21 1999-10-26 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5486161A (en) * 1993-02-02 1996-01-23 Zomed International Medical probe device and method
US5766633A (en) * 1993-04-22 1998-06-16 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US6100298A (en) * 1993-04-22 2000-08-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5955503A (en) * 1993-04-22 1999-09-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5472441A (en) * 1993-11-08 1995-12-05 Zomed International Device for treating cancer and non-malignant tumors and methods
US6958062B1 (en) 1993-11-08 2005-10-25 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US5458597A (en) * 1993-11-08 1995-10-17 Zomed International Device for treating cancer and non-malignant tumors and methods
US6071280A (en) * 1993-11-08 2000-06-06 Rita Medical Systems, Inc. Multiple electrode ablation apparatus
US20060247616A1 (en) * 1993-11-08 2006-11-02 Rita Medical Systems, Inc. Ablation treatment apparatus
US5928229A (en) * 1993-11-08 1999-07-27 Rita Medical Systems, Inc. Tumor ablation apparatus
US20050033279A1 (en) * 1993-11-08 2005-02-10 Rita Medical Systems, Inc. RF treatment apparatus
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5529568A (en) * 1994-03-18 1996-06-25 Surgery Futures Research, Inc. Magnetic operating table
US5593379A (en) * 1994-03-18 1997-01-14 Surgery Futures Research, Inc. Magnetic operating table
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6180140B1 (en) 1994-04-22 2001-01-30 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5976569A (en) * 1994-09-29 1999-11-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6346242B1 (en) 1995-03-31 2002-02-12 Emishpere Technologies, Inc. Compounds and compositions for delivering active agents
US6428780B2 (en) 1995-03-31 2002-08-06 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6071510A (en) * 1995-03-31 2000-06-06 Emisphere Technologies, Inc. Modified amino acids and compositions comprising the same for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US6461545B1 (en) 1995-06-07 2002-10-08 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US6100285A (en) * 1995-06-07 2000-08-08 Emisphere Technologies, Inc. Method of solubilizing itraconazole
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5667806A (en) * 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5951547A (en) * 1995-08-15 1999-09-14 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US6132425A (en) * 1995-08-15 2000-10-17 Gough; Edward J. Cell necrosis apparatus
US5925042A (en) * 1995-08-15 1999-07-20 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US5913855A (en) * 1995-08-15 1999-06-22 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
US8734439B2 (en) 1995-08-15 2014-05-27 Angiodynamics, Inc Ablation apparatus and method
US5980517A (en) * 1995-08-15 1999-11-09 Rita Medical Systems, Inc. Cell necrosis apparatus
US6059780A (en) * 1995-08-15 2000-05-09 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method with cooling element
US6080150A (en) * 1995-08-15 2000-06-27 Rita Medical Systems, Inc. Cell necrosis apparatus
US6090105A (en) * 1995-08-15 2000-07-18 Rita Medical Systems, Inc. Multiple electrode ablation apparatus and method
US6084112A (en) * 1995-09-11 2000-07-04 Emisphere Technologies, Inc. Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones
US7417022B2 (en) 1996-03-29 2008-08-26 Mhr Institutional Partners Iia Lp Compounds and compositions for delivering active agents
US6375983B1 (en) 1996-06-14 2002-04-23 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US7553872B2 (en) 1997-02-07 2009-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6242495B1 (en) 1997-02-07 2001-06-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8686154B2 (en) 1997-02-07 2014-04-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9095610B2 (en) 2004-02-20 2015-08-04 Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US20110076767A1 (en) * 2004-02-20 2011-03-31 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US20100260780A1 (en) * 2004-02-20 2010-10-14 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20090082611A1 (en) * 2004-02-20 2009-03-26 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20060057211A1 (en) * 2004-02-20 2006-03-16 Michael Chorny Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US9028829B2 (en) 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20100241058A1 (en) * 2009-03-19 2010-09-23 Ahmed Syed Yosuf Oct guided tissue ablation
US9345498B2 (en) 2009-11-02 2016-05-24 Pulse Therapeutics, Inc. Methods of controlling magnetic nanoparticles to improve vascular flow
US9339664B2 (en) 2009-11-02 2016-05-17 Pulse Therapetics, Inc. Control of magnetic rotors to treat therapeutic targets
US10029008B2 (en) 2009-11-02 2018-07-24 Pulse Therapeutics, Inc. Therapeutic magnetic control systems and contrast agents
US10159734B2 (en) 2009-11-02 2018-12-25 Pulse Therapeutics, Inc. Magnetic particle control and visualization
US10813997B2 (en) 2009-11-02 2020-10-27 Pulse Therapeutics, Inc. Devices for controlling magnetic nanoparticles to treat fluid obstructions
US11000589B2 (en) 2009-11-02 2021-05-11 Pulse Therapeutics, Inc. Magnetic particle control and visualization
US11612655B2 (en) 2009-11-02 2023-03-28 Pulse Therapeutics, Inc. Magnetic particle control and visualization
US20130225904A1 (en) * 2012-02-29 2013-08-29 University Of Virginia System and method for magnetic control of an anesthetic
US9883878B2 (en) 2012-05-15 2018-02-06 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
US10646241B2 (en) 2012-05-15 2020-05-12 Pulse Therapeutics, Inc. Detection of fluidic current generated by rotating magnetic particles
US20200069928A1 (en) * 2017-05-29 2020-03-05 Bionaut Labs Ltd. Triggering of payload release from miniaturized devices
US11918315B2 (en) 2019-05-02 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles

Similar Documents

Publication Publication Date Title
US3474777A (en) Method of administering therapeutic agents
US4569836A (en) Cancer treatment by intracellular hyperthermia
TW426532B (en) Method for heating a substance, magnetic material, and assembly for use in treating a biological material
US4106488A (en) Cancer treatment method
US5705195A (en) Magnetically responsive composition for carrying biologically active substances and methods of production and use
US4303636A (en) Cancer treatment
Babincová et al. Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field
Nijsen et al. Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours
RU2199348C2 (en) Novel radiopharmaceutical compositions and matrices and their using
Mumper et al. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors
JP2004511576A (en) Polymer-based radionuclide-containing particulate material
US20060025713A1 (en) Magnetic particle-based therapy
WO1993016735A1 (en) Use of aggregated proteins to prolong retention time of a therapeutic agent adjacent a targeted site such as a tumor
US5424288A (en) Method of treating solid tumor cancers utilizing macro aggregated proteins and colloidal radioactive phosphorous
JP2010516705A (en) Susceptor and its use in hyperthermia
Hnatowich et al. Dysprosium-165 ferric hydroxide macroaggregates for radiation synovectomy
EP0979656B1 (en) Composition containing radioisotopes immobilised on solid particles, and its use in brachytherapy
US4849209A (en) Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
US5026538A (en) Method of treating arthritis, including rheumatoid arthritis, with 166 Holmium radionuclide
US5061475A (en) Composition and method of treatment of arthritis and related diseases with holmium-166 radionuclides
Schubiger et al. 90Y-resin particles—Animal experiments on pigs with regard to the introduction of superselective embolization therapy
DE2828941C2 (en)
Garin et al. Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat
Häfeli et al. Magnetically targeted microspheres for intracavitary and intraspinal Y-90 radiotherapy
Dormer et al. Magnetically-targeted, technetium 99m-labeled nanoparticles to the inner ear